Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

15.04.2020 | short review | Ausgabe 3/2020 Open Access

memo - Magazine of European Medical Oncology 3/2020

Neoadjuvant chemoradiotherapy in rectal cancer

Are there new drug combinations on the horizon?

memo - Magazine of European Medical Oncology > Ausgabe 3/2020
MD, PhD Christoph Reinhold Arnold, MD Julian Mangesius, MD Robert Jäger, MD Ute Ganswindt
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Neoadjuvant chemoradiotherapy is a well-established standard treatment for locally advanced rectal cancer and has led to a remarkable improvement in local control. However, distant recurrences still pose a notable threat and local failure, albeit increasingly rare, can lead to unfavorable clinical situations. In this short review, we discuss three promising new strategies to improve rectal cancer treatment: total neoadjuvant therapy, short course radiotherapy, and immune checkpoint inhibitors.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2020

memo - Magazine of European Medical Oncology 3/2020 Zur Ausgabe